Papers by Maria-cristina Apavaloaie
Contact address: Alina Hohaci, MD, Discipline of Cardiology, “Prof. Dr. George I. M. Georgescu” I... more Contact address: Alina Hohaci, MD, Discipline of Cardiology, “Prof. Dr. George I. M. Georgescu” Institute of Cardiovascular Diseases, Carol I Avenue, no. 50, Iasi, Romania. E-mail: [email protected] 1 Discipline of Cardiology, “Prof. Dr. George I. M. Georgescu” Institute of Cardiovascular Diseases, Iasi, Romania 2 “Grigore T. Popa” University of Medicine and Pharmacy, Iasi, Romania 3 Department of Interventional Cardiology, “Prof. Dr. George I. M. Georgescu” Institute of Cardiovascular Diseases, Iasi, Romania 4 Discipline of Cardiothoracic Surgery, “Prof. Dr. George I. M. Georgescu”, Institute of Cardiovascular Diseases, Iaşi, România Abstract: Introduction – Takotsubo cardiomyopathy (TCM) is a cardiac condition that mimics the clinical presentation of acute coronary syndrome, but without any evidence of obstructive atherosclerotic coronary artery disease. The prognosis is usually good, with improvement of the left ventricular (LV) dysfunction within a few weeks. There are some ...
International Urology and Nephrology, 2014
MEDLINE to January 2014 and reference lists without language restriction. Meta-analysis using a r... more MEDLINE to January 2014 and reference lists without language restriction. Meta-analysis using a random-effects model was done for all-cause and cardiovascular mortality, hospitalization for heart failure, changes in clinical assessment of HF, serum sodium concentration (Na), kidney function and treatment-specific side effects. Results We identified 13 trials and 5,525 participants. In 10 trials, participants received standard therapy for HF. In low-quality evidence, VRAs in patients with HF had no effect on all-cause mortality risk ratios (RR 0.98; CI 0.88-1.08), cardiovascular mortality (RR 1.03; CI 0.91-1.16) or change in creatinine mean difference (MD −0.01; CI −0.10 to 0.09 mg/dL), but reduced body weight by 0.8 kg from baseline (MD −0.83; CI −1.10 to −0.55 kg) and increased Na (MD 2.61; 95 % CI 1.88-3.35 mmol/L). Compared with placebo, VRAs increased the risk of adverse events by 14 % (RR 1.14; CI 1.04-1.26). Studies were generally limited to short-term follow-up with limited data available on patient important outcomes. Conclusions Vasopressin receptors antagonists may reduce body weight and increase Na but do not improve all-cause mortality, cardiovascular mortality or kidney function. In addition, acceptability of long-term treatment side effects and hospitalization appears problematic.
Uploads
Papers by Maria-cristina Apavaloaie